The global Transfection Reagents and Equipment Market was valued at USD 715.34 million in 2016 and is projected to reach USD 1636.46 million by 2025, growing at a CAGR of 7.43% from 2017 to 2025.
Transfection reagents are a part of novel biotechnology techniques. There is high demand of transfection solutions for efficient delivery of DNA, siRNA, oligos, and RNA into adherent and suspension cells, including hard-to-transfect cells. The market is thus expected to grow during the forecast period.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Technological Advancements in Transfection Technology
1.2 Global Alliances Among Leading Research Institutes to Trigger Drug Discovery
1.3 Increase in R&D Spending and Research Activities By Pharmaceutical and Biotech Companies
1.4 Growing Research Activities in Cell Science
1.5 Increase in Demand for Synthetic Genes
1.6 Rising Incidence of Cancer Worldwide
2. Market Restraints
2.1 Selective Effectiveness of Transfection Reagents
2.2 Home Brew Reagents Restrict Sale of Commercial Kits
2.3 High Reagent Cost
Market Segmentation:
1. Global Transfection Reagents and EquipmentMarket, by End User:
1.1 Academics & Research Institutes
1.2 Pharmaceutical & Biotechnology Companies
2. Global Transfection Reagents and EquipmentMarket, by Application:
2.1 Biomedical Research
2.1.1 Gene Expression Studies
2.1.2 Cancer Research
2.1.3 Transgenic Models
2.2 Protein Production
2.3 Therapeutic Delivery
3. Global Transfection Reagents and Equipment Market, by Product:
3.1 Reagents
3.2 Equipment
4. Global Transfection Reagents and Equipment Market, by Method:
4.1 Biochemical Methods
4.1.1 Lipofection
4.1.2 Calcium Phosphate
4.1.3 DEAE-Dextran
4.1.4 Dendrimers
4.2 Physical Methods
4.2.1 Electroporation
4.2.2 Nucleofection
4.2.3 Others
4.3 Viral Methods
4.3.1 Adenoviruses
4.3.2 Retroviruses
4.3.3 Adeno associated Viruses
5. Global Transfection Reagents and Equipment Market, by Region:
5.1 North America (U.S., Canada, Mexico)
5.2 Europe (Germany, UK, France, Rest of Europe)
5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
5.4 Latin America (Brazil, Argentina, Rest of Latin America)
5.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Thermo Fisher Scientific Inc. (Life Technologies)
2. Promega Corporation
3. Qiagen N.V.
4. F. Hoffmann-La Roche Ltd
5. Bio-Rad Laboratories, Inc.
6. Maxcyte, Inc.
7. Lonza Group Ltd.
8. Merck KGaA
9. Polyplus-Transfection Sa (Subsidary of Archimed)
10. Mirus Bio LLC.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Transfection Reagents and EquipmentMarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL TRANSFECTION REAGENTS AND EQUIPMENTMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENTMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY END USER
5.1 Academics & Research Institutes
5.2 Pharmaceutical & Biotechnology Companies
6 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY APPLICATION
6.1 Biomedical Research
6.1.1 Gene Expression Studies
6.1.2 Cancer Research
6.1.3 Transgenic Models
6.2 Protein Production
6.3 Therapeutic Delivery
7 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY PRODUCT
7.1 Reagents
7.2 Equipment
8 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY METHOD
8.1 Biochemical Methods
8.1.1 Lipofection
8.1.2 Calcium Phosphate
8.1.3 DEAE-Dextran
8.1.4 Dendrimers
8.2 Physical Methods
8.2.1 Electroporation
8.2.2 Nucleofection
8.2.3 Others
8.3 Viral Methods
8.3.1 Adenoviruses
8.3.2 Retroviruses
8.3.3 Adeno associated Viruses
9 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENTMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
10 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENTMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies
11 COMPANY PROFILES
11.1 Thermo Fisher Scientific Inc. (Life Technologies)
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments
11.2 Promega Corporation
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments
11.3 Qiagen N.V.
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments
11.4 F. Hoffmann-La Roche Ltd
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments
11.5 Bio-Rad Laboratories, Inc.
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments
11.6 Maxcyte, Inc.
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments
11.7 Lonza Group Ltd.
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments
11.8 Merck KGaA
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments
11.9 Polyplus-Transfection Sa (Subsidary of Archimed)
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments
11.10 Mirus Bio LLC.
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments
12 Appendix
12.1 Related Reports